|
1869
|
Bakeley [120]
|
Invented skin tests for allergy diagnosis
|
|
1902
|
Richet and Portier [121]
|
Described the term anaphylaxis
|
|
1906
|
Von Pirquet [122]
|
Used the term “supersensitivity without immunity” to describe symptoms of inhalant allergy and positive skin tests
|
|
1913
|
Clowes [123]
|
Publication of the first successful trial of ragweed subcutaneous immunotherapy
|
|
1919
|
Ramirez [124]
|
Recognized the phenomenon of sensitization, when reporting new horse allergy in a patient who received blood from a horse-allergic donor
|
|
1921
|
Prausnitz and Küstner [120]
|
Described Prausnitz–Küstner (P–K) test, known to sensitize the skin of healthy subjects, through a „transferable sensitization factor“
|
|
1930
|
Coca [125]
|
Introduced the concept of atopy (hereditary tendency to become allergic) and the term “atopic reagin” as the responsible factor
|
|
1960+
|
Fisherman [126]; Mackay [127]
|
First epidemiological studies of allergy and cancer risk
|
|
1964
|
Ogilvie [128]
|
Described reagin-like antibodies in animals immune to helminth parasites
|
|
1965, 1967
|
Johansson et al. [129]
|
A new myeloma protein named IgND found to inhibit P-K activity
|
|
1966
|
Ishizaka [130]
|
Working on an antiserum that could deplete the P-K activity, containing a molecule named γE
|
|
1967
|
Wide et al. [131]
|
RAST (Radio-Allergo Sorbent test) assay development
|
|
1968
|
Bennich et al. [1]
|
Immunoglobulin E discovery announcement
|
|
1971
|
Ishizaka [132]
|
Description of IgE-mediated histamine release
|
|
1971
|
Augustin [133]
|
Published one of the first papers describing IgE levels in cancer and non-cancer patients
|
|
1974
|
Ishizaka and Tomioka [134]
|
First description of IgE-receptors
|
|
1992+
|
Mills et al. [135]; Kallen et al. [136]; Vesterinen et al. [137]; Turner et al. [138]
|
Some first large-scale prospective epidemiological studies of allergy and cancer risk
|
|
1999
|
Gould et al. [139]
|
Reported that IgE antibody-dependent cytotoxicity could be used in suppression of ovarian tumours
|
|
1999
|
Milgrom et al. [140]
|
First randomized placebo-controlled trial using a recombinant humanized monoclonal antibody against IgE (rhuMAb-E25, later named Omalizumab) as treatment in patients with asthma
|
|
2005+
|
Lindelof et al. [141]; Van Hemelrijck M [142]
|
First epidemiological studies of pre-diagnostic IgE levels and total cancer risk
|
|
2008+
|
Jensen-Jarolim et al. [143]; Penichet and Jensen-Jarolim [120]; Platzer [26]
|
Defined the new field of AllergoOncology and the potential mechanisms through which IgE has role in tumour surveillance
|
|
2011+
|
Calboli et al. [22]; Schlehofer et al. [21]; Schwartzbaum et al. [20]
|
First epidemiological studies of pre-diagnostic IgE levels and specific cancer risk
|
|
2016
|
Simpson et al. [144]
|
Dupilumab, a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit, used for treatment in patients with moderate-to-severe atopic dermatitis
|
|
2018
|
Karagiannis SN et al. [145]
|
Initiation of first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen
|
|
2019
|
Ferastraoaru and Rosenstreich [34]
|
First longitudinal study of pre-diagnostic IgE deficiency and cancer risk
|
|
2020
|
Spicer JF et al. [80]
|
Interim data of the first phase-1 clinical study (NCT02546921) of IgE antibody MOv18 against an ovarian cancer antigen presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
|
